In the United States, most non-prescription drugs are available over-the-counter (OTC) in pharmacies and other stores. Experts have suggested that drug availability could be increased by establishing an additional class of non-prescription drugs that would be held behind the counter (BTC) but would require the intervention of a pharmacist before being dispensed; a similar class of drugs exists in many other countries. Although the Food and Drug Administration (FDA) has not developed a detailed proposal for a BTC drug class, it held a public meeting to explore the public health implications of BTC drug availability. This book explores the public health benefits of behind the counter availability of certain drugs without a prescription. In particular, the debate whether behind the counter may improve patient access to safe and effective drug products is discussed. This book looks at the pharmacist, infrastructure, and cost-related issues which would have to be addressed before a BTC drug class could be established in the United States.
Preface; Non-prescription Drugs:: Considerations Regarding a Behind-the-Counter Drug Class; Food & Drug Administration Behind the Counter Availability of Certain Drugs, Public Meeting; Index.
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.